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Arterial reconstructive surgery has been attended by a modest 
early failure rate due to thrombosis of endarterectomized segments or 
22 
vein bypass grafts. With the advent of coronary artery surgery, the 
importance of avoiding early failure due to thrombosis assumes even 
greater importance as thrombosis can result not only in failure to in- 
25 
crease blood supply to the myocardium but in mortality as well. 
Thrombosis after surgical or other trauma to a vessel wall is most 
53 
likely initiated by adherence of platelets to the site of injury. 
Therefore, attempts to reduce the incidence of thrombosis and consequent 
failure of reconstructive vascular surgery can be directed at inter¬ 
rupting the initial platelet mediated steps. A number of pharmacologic 
59 
agents have been shown in vitro and in vivo to affect platelets, 
and an attempt has been made to apply one of these, dextran, to arterial 
31 
surgery in clinical practice. The present studies then were directed 
at the development of a model for intra-arterial thrombosis which would 
clot consistently and which would resemble the clinical situation. Then, 
the ability of two agents previously shown to have effects on platelets, 
dipyridamole and aspirin, to alter the rate of thrombosis were tested 
against this model. 
Review of the Literature: 
Early failure due to thrombosis constitutes an important 
problem in most large series of arterial reconstructive procedures for 
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ischemic vascular disease of the lower limb. Gutelius ej: al. reported 
early failure rates of 18% for saphenous vein grafts and 30% for 
38 
endarterectomy in treating superficial femoral artery disease. 
DeWeese e_t al. reported a 287, early failure rate in femoro-popliteal 
23 22 
saphenous vein grafts and 15% early failures with endarterectomy. 
Darling £t al_. were somewhat more successful with only 7.8% early fail- 
20 
ures with femoro-popliteal vein grafts. Vein grafts to tibial artery 
segments with both proximal and distal arterial occlusions thrombosed 
52 
in 9 or 31 patients reported by Mannick ej: al. In vein grafts to the 
distal tibial arteries at the ankle, Garret et al. reported 7 early 
34 
failures due to thrombosis in 57 cases. Harrison and his group reported 
a 1007o patency rate at the end of hospitalization in 25 patients with 
superficial femoral artery disease utilizing "eversion thromboendarterec- 
tomy", but 4 (16%) required reoperation before discharge because of 
41 
thrombosis of reconstructed segments. Similar results were obtained 
14 
by Connolly et_ al. with eversion thromboendarterectomy. Each of these 
series of reconstructive procedures then was attended by a significant 
early failure due to thrombosis. 
Coronary artery surgery, although less extensively reported 
because of its recent advent, shows similar early failure rates. 
Dilley e_t al. in an early report of endarterectomy for coronary disease 
indicated that 127o of their 25 patients died with thrombosis in the 
25 
endarterectomized segment. Mitchel and his group reported a series of 
128 patients with saphenous vein grafts in whom 10 had thrombosed at 
56 
least one graft. However, 8 additional patients died without any re¬ 
port on the status of their grafts. Green et al. described 6 patients 
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with thrombosed vein grafts among 82 cases but the total early graft 
3 6 
failure rate was again not evaluated. Early thrombosis of a graft 
or endarterectomized segment may be a significant problem in coronary 
artery surgery as it has been in peripheral vascular surgery. 
Substantial evidence exists that platelets play a central 
role in thrombus formation after injury to the vessel wall. Bizzozero 
6 
depicted the role of platelets in thrombus formation in 1882. Ashford 
and Freiman found that simply grasping a vessel with a forceps produced 
disruption of the endothelium of the vessel wall and resulted in the 
formation of a thrombus composed primarily of platelets at the site of 
3 
injury. French £t a_l. found that after electrical injury to the wall 
of a small vessel, endothelial cells were lost from the intima of the 
vessel wall and that platelet thrombi appeared at these sites within a 
32 72 5 
few seconds. Spaet and Erichson and Baumgartner et_ al. reported 
similar findings regarding the role of platelets in thrombosis after 
82 32 A-7 
vascular injury. Zucker, French eE ad.., and Hovig ejt ad.. have 
also emphasized the primary role of platelets in the arrest of bleeding 
from the end of a transected artery. The importance of platelets in 
thrombosis after arterial surgery has been demonstrated by Evans and 
Mustard who found a significant correlation between platelet adhesive¬ 
ness in a glass bead column and the onset of thrombosis after dacron 
29 
grafts, endarterectomy, or saphenous vein grafts. In addition, 
Rowsell et: a_l. have found that thrombocytopenic swine will not form 
thrombi in an extracorporeal shunt unless they are transfused with 
platelet rich plasma.^ Thus, platelets play a primary role in thrombus 
formation after injury to the vessel wall, and it seems very likely that 
they are also involved in thrombosis after arterial reconstructive surgery. 
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The evolution of a platelet thrombus after vascular injury 
involves a fairly well understood sequence of events from the initial 
sticking of platelets to the vessel wall through growth of the thrombus, 
3 32 72 
stabilization, and ultimately organization. Anatomic studies ’ ’ have 
shown that the initial event in thrombus formation is the adherence of 
platelets to subendothelial structures after loss of the endothelial 
cells, or to perivascular connective tissue fibers after transection 
of small vessels. The substance in the perivascular tissue which in¬ 
duces platelet aggregation has been reasonably certainly identified as 
collagen by electron microscopy. In vitro studies have 
clearly demonstrated the ability of collagen to induce platelet aggre¬ 
gation. The loss of native structure by heating, by treatment with 
collagenase, or by blocking the epsilon amino groups of lysine of the 
collagen molecule results in the loss of the ability of collagen to 
80 
induce platelet aggregation. The nature of the substance in the sub¬ 
endothelial layer of the vessel wall which induces platelet aggregation 
after loss of the endothelium is still somewhat in doubt. French and 
his co-workers described platelets adhering to elastic tissue and fine 
32 
fibers. Spaet and Erichson concluded, however, that collagen was the 
active substance in the subendothelial layer as suspensions of elastic 
72 
tissue did not induce platelet aggregation in vitro. Baumgartner e_t ah 
more recently have described the adherence of platelets to a non- 
collagenous subendothelial structure after diffuse injury to the aorta 
5 
in an experimental animal. Hughes and Mahieu have shown that basement 
membrane prepared from renal tubules can induce platelet aggregation 
in vitro and have hypothesized that the basement membrane in vessels is 
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the important substance in bringing about platelet aggregation in vivo. 
3 32 4-7 12 
Several investigators 3 ’ 5 have stated that fibrin formation does 
not seem to precede platelet adherence to any of these structures. The 
initial step in thrombus formation then is the adherence of platelets 
to one or more subendothelial or perivascular structures. 
The exposure of platelets to these subendothelial and peri¬ 
vascular structures results not only in the adherence of platelets, but 
also in morphologic changes in the platelets and the release of specific 
active substances to induce further platelet aggregation. Platelets in 
contact with collagen fibers in vivo show formation of pseudopodia,^ 
32 32 
loss of granules, and breaks in the cell membrane, and similar 
changes have been demonstrated in vitro with collagen induced platelet 
45 
aggregation. These morphologic changes are associated with the re¬ 
lease of compounds which show further aggregating activity toward 
platelets, including adenosine diphosphate (ADP)^^>54,73 seroton^nj^4 
, u • 59,75 • . . 73 , 50 
and epinephrine, m a calcium and energy dependent process. 
ADP was initially demonstrated to aggregate platelets in vitro by 
33 7 
Gaarder ej: aj.. and Born, and has subsequently been shown to produce 
changes in platelet shape similar to those found in a developing platelet 
plug. ^ The application of ADP to areas of minor injury in vessels leads 
43 44 
to the enhancement of white thrombus formation, 3 and the intravenous 
infusion of ADP can increase the amount of thrombus formed in an extra¬ 
corporeal shunt, decrease the clotting time, transiently decrease the 
platelet count, and cause the formation of platelet aggregates in the 
vasculature of a variety of different organs 
60 
In addition, ADP in 
sufficient concentration can cause the release of more ADP and serotonin 
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from platelets.Serotonin has also been shown to be capable of pro- 
62 
during platelet aggregation, and of increasing the rate of thrombus 
43 44 
formation in areas of minor injury to a vessel wall. Along with 
ADP and serotonin, catecholamines have been shown to have potent effects 
on platelet aggregation. Epinephrine and norepinephrine can induce 
54,63 
platelet aggregation in vitro, and can bring about the release of 
54 
ADP and serotonin from platelets. Epinephrine can also markedly en- 
75 75 2 
hance the ability of collagen, thrombin, and ADP to induce platelet 
aggregation. Of these three active agents released by the platelet 
collagen interaction, it is currently believed that ADP is the most im- 
59 
portant physiologically. The most compelling evidence for this 
hypothesis comes from the observations that inhibitors of ADP aggrega¬ 
tion can inhibit aggregation induced by a variety of different agents 
. , ,, .62 . u . 62 u u. 42,62 J 73 
including serotonin, epinephrine, thrombin, and collagen, 
59 43 83 
while antagonists of catecholamines, serotonin, and thrombin do 
not affect ADP mediated platelet aggregation. Thus, the initial stages 
of thrombus formation and growth after vascular injury result from a 
specific interaction between collagen or other substances in the vessel 
wall and platelets from the blood. This leads, in turn, to specific 
morphologic changes in the platelets and the release of active compounds 
which then induce more platelets to aggregate around the site of injury. 
The future of the platelet thrombus at the site of injury then 
depends in part on the activation of the plasma coagulation system. 
The aggregation of platelets in vitro by collagen, ADP, epinephrine, 
and serotonin is associated with platelet factor 3 becoming available 
39 
to activate the plasma coagulation system. This "factor" is thought 
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to be a lipoprotein moiety which remains attached to the platelet mem¬ 
brane and serves as a catalytic site for the interaction of plasma 
39,53 
coagulation factors. The activation of the plasma coagulation 
53 
factors results in the generation of thrombin and then fibrin, which can 
53 58 
in turn influence the fate of the platelet plug. 5 Thrombin has 
actions similar to those of collagen in inducing platelet aggregation, 
producing morphologic changes, and causing the release of active sub- 
42,54,62,73 
stances. In addition to its direct effects on platelets, 
53 
thrombin catalyses the conversion of fibrinogen to fibrin. Both 
Zucker*^ and Hovig and his group^ have demonstrated that the formation 
of fibrin is necessary for the stabilization of the platelet plug. In 
experimental animals with clotting factor deficiencies who do not form 
fibrin, the initial arrest of bleeding from the transected end of a 
vessel by the formation of a platelet plug is followed by a high inci¬ 
dence of re-bleeding.^ ’ ^ The plasma coagulation system then is im¬ 
portant in the growth and stabilization of the platelet thrombus. 
There is also some inconclusive evidence that the fibrinogen 
component of the coagulation system is important in primary platelet 
aggregation as well. Cross found in vitro that the addition of 
fibrinogen or plasma to washed platelets led to a marked increase in 
the response of platelets to ADP. ^ Similar findings have been reported 
by Weiss and Rogers in the study of two patients with cogenital 
79 
afibrinogenemia. However, Gugler and Luscher reported normal platelet 
37 
aggregation in a similar patient. The exact role of fibrinogen in 
the primary processes of platelet aggregation remains somewhat unclear. 
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With functioning platelet aggregation and plasma coagulation 
systems, the final determinant of the extent of the thrombus formed 
after vascular injury depends on the patterns of blood flow in the area 
5 8 
of the injury. Mustard et: a_l. theorized that laminar flow would 
favor the restriction of further thrombus growth by diluting the ADP, 
serotonin, epinphrine, and thrombin as they are formed from the de- 
5 8 
veloping platelet plug. Disturbed flow with eddy formation and areas 
of stagnation would allow the buildup of these active substances and 
5 8 
favor the further growth of the thrombus. This reasoning has been 
verified by this group who found that diffuse injury to the aorta of a 
pig resulted in the buildup of thrombus at areas of disturbed flow 
such as the bifurcation, but caused only a thin layer of thrombus 
5 8 
formation in the areas of laminar flow. This group of workers also 
reported similar findings regarding the formation of thrombi in an 
extracorporeal shunt.^ These observations correlate with clinical 
observations that the chances for the success of saphenous vein grafts 
are increased when they are inserted into non-diseased portions of the 
vessel with good runoff and with the finding that endarterectomy has a 
higher success rate when this procedure leaves a smooth transition be¬ 
tween the endarterectomized segment and the remainder of the vessel 
23 
wall. With grafts inserted into diseased segments of vessel and in 
endarterectomies without a smooth transition, turbulent flow with eddy 
formation favors the accumulation of platelet aggregating substances. 
Similarly, poor runoff favors the buildup of these substances because 
of sluggish flow. Thus, the pattern of blood flow through the injured 
segment of vessel inlfuences the ultimate growth of the thrombus. 
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After the initial platelet-fibrin thrombus is formed, it is 
53 58 
gradually replaced with fibrin. ’ The platelets gradually dissolve, 
and over a period of time ranging up to 14 days the fibrin and platelet 
remnants are phagocytosed by mononuclear cells and replaced by a mass 
53 
rich in smooth muscle and collagen covered by endothelium. However, 
if the thrombus has completely occluded the lumen the resolution of the 
thrombus may leave a non-patent fibrous cord. 
Numerous attempts have been directed at attempting to define 
agents which would inhibit platelet aggregation. The first group of 
agents discovered were the structural analogues of ADP, adenosine and 
g 
2 chloroadenosine. Born found that the addition of either compound to 
an in vitro system before the addition of ADP inhibited the normal 
aggregation by ADP, and Born et: al. also reported that the intravenous 
infusion of adenosine or 2 chloroadenosine prevented the formation of 
a white thrombus at the site of an arterial injury."^ Clayton, Born, 
and Cross then investigated other structural analogues of adenosine and 
found that adenosine monophosphate (AMP) also inhibited ADP-mediated 
platelet aggregation. However, other compounds with small structural 
13 
changes in the adenosine moiety were lacking in activity. Born £t al. 
also noted that adenosine and 2 chloroadenosine had potent vasodilator 
10 
action and subsequently investigated the relationship between the 
vasodilating actions of adenosine analogues and their ability to inhibit 
ADP mediated platelet aggregation. Their findings showed a close cor- 
9 
relation between vasodilator and inhibitory activities. Emmons e_t al. 
then investigated dipyridamole because of its vasodilator actions and 




crease the adenosine level in whole blood. This group found that incu¬ 
bation of dipyridamole with platelet rich plasma decreased aggregation 
27 
by ADP. In addition, they found that an intravenous infusion of 
dipyridamole markedly decreased the formation of thrombi at sites of 
2 8 
vessel injury. However, long term human ingestion did not affect 
platelet aggregation in vitro induced by ADP, serotonin, or norepine- 
27 
phrine. Didisheim subsequently showed that dipyridamole decreased 
the rate of occlusion of mesenteric vessels after electrical injury in 
24 
the rat. Further studies have revealed that dipyridamole inhibits 
17 59 
platelet aggregation induced by collagen and thrombin in vitro, 3 
17 59 17 59 84 
and inhibits the release of ADP * and serotonin ’ 3 by these 
platelet aggregating agents. Dipyridamole given in vivo inhibited plate¬ 
let aggregation induced in vitro by collagen and thrombin and increased 
the bleeding time from the cut end of a mesenteric vessel in rabbits.^ 
These studies have also indicated that dipyridamole decreases the uptake 
, 17 , . 17,69 
of glucose, adenosine and serotonin"^ by platelets, and it has 
been hypothesized that its actions result from this generalized metabolic 
69 
inhibition. Dipyridamole has very recently been shown to decrease 
18 
the rate of thrombosis after mechanical endarterectomy in dogs, to 
40 
decrease the platelet turnover and incidence of thromboembolic com- 
74 
plications in patients with prosthetic heart valves, and to decrease 
2 8 
the amount of platelet aggregation in a heart lung pump oxygenator.“ 
In addition to dipyridamole, Emmons ej: al. also investigated 
2 8 
prostaglandin because of its vasodilator effects.^ They found that 
PGE^ inhibited ADP, serotonin, thrombin and norepinephrine induced 




injured vessels.*" Further studies have shown that collagen induced 
aggregation is also inhibited by PGE^, and that PGE^ will decrease the 
release of radioactively labeled serotonin from platelets exposed to 
collagen and thrombin.Kinlough-Rathbone ej: al. suggested that these 
effects on platelets might result from the actions of PGE^ to increase 
intra-platelet cyclic AMP,"*^ but Ball et ajL. could not find a correla¬ 
tion between platelet cyclic AMP and inhibition of collagen induced 
4 
platelet aggregation. However, they did find that theophylline, a 
methyl xanthine which inhibits the phosphodiesterase enzyme which 
breaks down cyclic AMP, enhanced the effects of PGE^ to inhibit collagen 
4 
induced platelet aggregation. Salzman has concluded in a recent re¬ 
view that the role of cyclic AMP in platelet aggregation and in its 
inhibition by compounds such as PGE-^ is not clear and bears further 
70 
investigation. 
Because of the evidence of the importance of catecholamines 
in platelet aggregation, various inhibitors of the cardiovascular ac¬ 
tions of the catechols have been investigated. Phentolamine, an alpha 
blocking agent, has been shown to inhibit epinephrine induced platelet 
63 
In addition, alpha blocking agents can reduce the 
75 
aggregation 
ability of collagen and thrombin to induce platelet aggregation. 
Significantly, the beta blocking agent propranolol was much less effective 
in inhibiting platelet aggregation.Thus, an alpha receptor has been 
postulated to reside on the platelet membrane which is closely involved 
in platelet aggregation. 
The non-steroidal anti-inflammatory drugs constitute another 
class of agents which have effects on platelets. Mustard et al. found 
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that sulfinpyrazone could increase the platelet survival in rabbits 
although it did not significantly affect the formation of thrombus in 
an extracorporeal shunt.^ Packham et al. found that the addition of 
phenylbutazone or sulfinpyrazone to platelet rich plasma decreased the 
platelet aggregation induced by collagen, and decreased the amount of 
ADP and serotonin released.^ They also found that phenylbutazone 
could prolong the bleeding time from cut ends of mesenteric vessels. 
65 
However, they could demonstrate no change in the response of platelets 
to thrombin.^ in addition to these pyrazole anti-inflammatory com¬ 
pounds, aspirin has been shown to have marked effects on platelets and 
hemostasis. Gast reported that aspirin decreased platelet "stickiness", 
increased the bleeding time, and increased the incidence of post 
35 
tonsillectomy hemorrhage from 0.1% to 8.7%. Weiss and Aledort then 
reported that an oral dose of 3 grams of aspirin per day inhibited 
platelet aggregation induced by a connective tissue suspension in vitro 
and increased the bleeding time, but did not affect ADP-induced aggre¬ 
gation of platelets.^ Evans ej: al_. then showed that aspirin added to 
platelet rich plasma inhibited aggregation induced by collagen, 
thrombin, and antigen antibody complexes, and simultaneously reduced 
the release of ADP and serotonin in response to these aggregating sub- 
30 
stances. They also found that aspirin administration prolonged the 
platelet survival and reduced the amount of thrombus forming in an 
30 
extracorporeal shunt. Zucker and Peterson confirmed the effects of 
aspirin on serotonin release and also found that aspirin decreased the 
availability of platelet factor 3 after exposure of platelets to 
85 
aggregating stimuli. Weiss ej: aJL. reported similar findings regarding 
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the effects of aspirin on aggregation and release of ADP by connective 
tissue, and also found that aspirin reduced platelet aggregation in 
7 8 
response to epinephrine. Danese _et al. found that aspirin reduced the 
amount of thrombus formed after chemical and mechanical injury to the 
vessel wall in dogs.^5^ The mechanism by which aspirin inhibits 
platelet aggregation has been investigated by Al-Mondhiry et_ al., and 
this group concluded that it may result from acetylation of active 
sites on the platelet membrane.'” 
An additional class of agents which affect the biological 
membranes has been shown to inhibit platelet aggregation. Included in 
this group are a variety of antihistamines including promethazine and 
diphenhydramine. Both of these agents have been reported to decrease 
platelet aggregation in response to ADP, epinephrine, and collagen. 
A second group of membrane active drugs with effects on platelets are 
the tranquilizers and antidepressants. Chlorpromazine, amitryptiline, 
imipramine, nortryptiline, and norimipramine have all been shown to 
inhibit ADP, epinephrine, and collagen induced platelet aggregation as 
well.'*'* The local anesthetics comprise a third group of membrane 
active drugs with lidocaine, cocaine, and nupercaine reported to in- 
64 
hibit platelet aggregation in vitro. The precise mechanisms of 
action by which these various drugs act are unknown, but they have been 
classified together by Mustard and Packham because each has been demon- 
59 
strated in some systems to have effects on biological membranes. 
They have hypothesized that this common feature may underly their 
59 
ability to alter platelet aggregation. 
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Despit e the large number of agents demonstrated in a variety 
of experimental situations to affect platelets, only two agents have 
received any clinical application in arterial surgery. Heparin has 
been employed because of its effects on plasma coagulation factors, but 
59 
it has also been shown to have effects on platelets. It can inhibit 
thrombin induced aggregation of platelets and release of platelet 
59 
constituents, but it is ineffective against the actions of collagen 
on platelets except at concentrations greater than 10 units/ml 
59 71 
(10 mg/100 ml). 3 This latter dosage is equivalent to approximately 
8 mg/kg which is almost three times the generally accepted dose for full 
heparinization. In addition, heparin does not inhibit ADP induced 
59 
platelet aggregation even at these high doses. However, heparin does 
59 
prolong platelet survival in man. Salzman has reported that patients 
with "difficult situations" in peripheral artery reconstructions were 
71 
not aided by the addition of heparin to the regimen. Somewhat better 
results have been achieved with the use of dextran. Moncrief jet al. 
employed clinical dextran (average molecular weight 70,000) with autologous 
end to end vein grafts to the femoral arteries of dogs. This group re¬ 
ported an increase of over 100% in the patency rate with dextran.^ 
Winfrey and Foster utilized low molecular weight dextran (average 
molecular weight 40,000) during removal of the intima by mechanical 
means over a 2 cm length of artery with almost 5 times as many vessels 
81 
patent in the dextran as compared to the control group. Foster et. al. 
have reported that the employment of low molecular weight dextran im¬ 
mediately post operatively has significantly increased their success 
rate in peripheral arterial reconstructions.^ Recent work has 
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demons tra ted clinical dextran (macrodex) with an average molecular 
weight of 70,000 could increase the bleeding time and decrease platelet 
adhesiveness when given to patients. However, Cronberg and his group 
were unable to reproduce the effects on platelet adhesiveness when 
15 
macrodex was added to platelets in vitro. Similar but less potent 
15 
effects were observed with low molecular weight dextran by this group. 
Macrodex also has been shown to markedly reduce factor VIII activity in 
the blood, but the importance of this finding remains unclear as the 
role of factor VIII in platelet aggregation is not known. 
In summary, then, peripheral and coronary arterial recon¬ 
structive surgery are complicated by a recognized early failure rate 
due to thrombosis in most series, and it is likely that this thrombosis 
is initiated by platelets. The events in arterial thrombosis are 
reasonably well defined with platelet adherence to collagen or other 
subendothelial substance leading to the release of platelet aggregating 
substances from these adherent platelets. The platelet thrombus is then 
stabilized with fibrin via the plasma coagulation system with the pat¬ 
tern of blood flow being an important determinant of the ultimate ex¬ 
tent of the thrombus. Several agents have been shown to affect plate¬ 
lets and to alter thrombus formation after experimental injury via a 
variety of mechanisms. Relatively few attempts, however, have been made 
to apply these clinically to arterial reconstructive surgery. 
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MATERIALS AND METHODS 
The initial efforts in this study were directed at developing 
an arterial model which would parallel as closely as possible the events 
in clinical arterial surgery but which would also provide a consistently 
clotting system against which various agents could be evaluated. The 
adult mongrel dog was chosen as the experimental animal, and all dogs 
weighed between 22 and 28 kg. Intrabenous sodium pentobarbital 
(25 mg/kg) was employed for anesthesia, and all animals were placed 
supine on the operating table, intubated, and maintained on a volume 
respirator. Intravenous gallamine in 10 mg doses provided supplemental 
anesthesia. 
In Group I, consisting of 25 vessels in 13 dogs, 4 cm segments 
of femoral artery between the inguinal ligament and the knee, or 4 cm 
segments of common carotid artery were isolated under sterile condi¬ 
tions and the side brances were ligated and divided. All vessels mea¬ 
sured between 4 and 5 mm in external diameter after dissection. Blood 
flow was interrupted between atraumatic vascular clamps and a 3 cm 
logitudinal arteriotomy was created with Potts arterial scissors. A 
mechanical endarterectomy was then performed using an ordinary chemical 
spatula to develop a plane of dissection. The arteriotomy was then 
closed with a running 6-0 everting suture. Prior to the last stitches 
both proximal and distal occlusions were temporarily removed to flush 
blood clot forming secondary to stasis. 
Group II consisted of 11 vessels in 7 dogs and was identical 
to Group I except that the brachial arteries were employed. Vessels in 
this group measured 2 to 3 mm in diameter after dissection. 
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In Group III, consisting of 10 vessels in 7 dogs, 4 cm segments 
of femoral artery were isolated and the side branches were ligated and 
divided under sterile conditions. The following procedure was then 
employed to remove the intimal and muscularis layers of the vessel wall. 
Blood flow was interrupted between vascular clamps, and a solution con¬ 
taining 1 gram of the proteolytic enzyme pronase in 400 cc of normal 
saline (0.25%) was prepared. This solution of enzyme was then perfused 
for thirty minutes through the isolated segment of artery at 200 cc per 
minute via canulas inserted into two small longitudinal arteriotomies 
at either ends of the isolated segment. After perfusion, the vessels 
were flushed thoroughly with normal saline to remove residual pronase 
solution. The arteriotomies were then closed with 6-0 everting sutures 
and blood flow restored. 
Group IV consisted of 6 vessels in 4 dogs. The procedure in 
this group was identical to that performed in Group III except that 
the perfusate consisted of normal saline instead of pronase. All ves¬ 
sels were removed at 6 hours after perfusion. 
In Group V, consisting of 10 vessels in 5 dogs, the procedure 
was identical to that in Group III except that the dogs were given 250 mg 
of dipyridamole by mouth each day for 4 days prior to operation and then 
continued until the time of sacrifice at intervals from 6 hours to 6 
weeks after operation. 
Group VI consisting of 10 vessels in 5 dogs was similar to 
Group V except that 40 grains of aspirin (approximately 2.6 grams) was 
given to the animals the day preceding operation and each day thereafter 
until sacrifice 6 hours to 10 days after operation. 
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Patency of the vessel was determined in vivo by palpation of 
the femoral artery pulse distal to the site of perfusion, and at 
sacrifice by direct examination of the vessels. In addition, two micro- 
scopic sections were made of all vessels. One was stained with hema¬ 
toxylin and eosin, the other with Masson trichrome. 
The effects of pronase on the plasma coagulation system were 
evaluated by adding 4 drops of the 0.25% pronase solution to a plain 
glass test tube and to a citrated tube of venous canine blood. Lee 
White, prothrombin, and partial thromboplastin times were determined 




In Group I, of the 25 femoral and carotid arteries subjected 
to endarterectomy, 9 clotted within 6 hours after the restoration of 
blood flow. Microscopy demonstrated that the intima, internal elastic 
membrane, and part of the muscularis layers had been removed by the 
mechanical endarterectomy. In all cases there were platelets adherent 
to the damaged areas of the vessel wall, but in 16 vessels this was 
not sufficient to occlude the lumen of the vessel. 
In Group II, of the 11 brachial arteries endarterectomized, 
6 clotted within 6 hours. Microscopic findings were similar to those 
found in Group I. 
In Group III, all 10 vessels perfused with pronase showed 
loss of pulsations distal to the perfusion site within 3 hours after 
the restoration of blood flow. Gross inspection of the vessels showed 
clot occluding the lumen in the area of perfusion. Microscopy demon¬ 
strated that the intima and part of the muscularis layers of the wall 
had been removed by the proteolytic action of the pronase. The thrombus 
occluding the lumen was composed of a platelet mass containing fibrin 
with trapping of red and white blood cells, and was confined to the area 
perfused with pronase. (Figure 1). 
In Group IV, none of the vessels perfused with saline became 
occluded in 6 hours, at which time the dogs were sacrificed. Two of 
these 6 vessels were in dogs which had perfusion of pronase in the 
contralateral femoral artery which led to thrombus formation. Micro¬ 
scopy of the saline treated vessels revealed no disruption of the vessel 
wall and no thrombus formation. (Figure 2). 
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In Group V, of the 10 vessels perfused with pronase in 
animals treated with dipyridamole, 3 clotted acutely, 2 were patent at 
sacrifice 6 hours postoperatively, and 5 remained patent until sacrifice 
at 2 to 6 weeks after operation. In the vessels studied at 6 hours 
after perfusion, a slight amount of clot was seen grossly, and micro¬ 
scopic examination showed a thin layer of platelets and fibrin along 
the portion of the vessel perfused with pronase. (Figure 3). In the 
vessels studied at 2 to 6 weeks no clot was seen grossly and the inside 
of the vessel was covered with a smooth shiny lining. On microscopic 
examination, no platelet fibrin clot was seen. The luminal surface of 
the vessel wall at 2 weeks after the time of perfusion showed a fibro¬ 
blastic proliferation in the intimal area which appeared to be covered 
by a layer of endothelial cells (Figure 4). No unusual problems with 
hemostasis were noted in this group of dogs receiving dipyridamole. 
In Group VI, of the 10 vessels perfused with pronase in 
animals receiving aspirin, 9 remained patent until sacrifice at 6 hours 
to 10 days after operation. With this dose of aspirin there appeared 
to be a marked hemostatic defect. Even the smallest arterioles and 
venules required ligation or cautery for hemostasis. One animal not 
included in the above results died from massive and uncontrollable 
hemorrhage from arteriotomy suture lines despite all measures. A second 
animal, included in the series, developed large hematomas in both groins 
after operation. At 6 hours after perfusion pulses were palpable and a 
moderate amount of clot was visible on the vessel wall on gross examina¬ 
tion. The microscopic findings were similar to those in the vessels 
examined 6 hours postoperatively in Group V with a layer of platelet 
fibrin thrombus adherent to the damaged areas of the vessel wall. The 




Groups I and II demonstrated that mechanical endarterectomy 
over a 3 cm length of vessel can produce a significant early thrombosis 
rate. The thrombosis rate is clearly related to the size of the vessel 
involved as femoral and carotid vessels measuring 4 to 5 mm in diameter 
became occluded with thrombus 36%, of the time while the incidence of 
occlusion increased to 60% in the 2 to 3 mm brachial arteries. The 
rates of occlusions, however, are less than those reported by Winfrey 
and Foster, who had a 95% occlusion rate after similar procedures in 
81 
dogs with 3.5 mm vessels. Microscopic examination in this study 
showed that platelets were involved in the thrombus formation in ac¬ 
cordance with previously cited observations of the events following 
3 
injury to the inner layers of the vessel wall. Because these mechanical 
endarterectomies did not provide a model of arterial thrombosis which 
would consistently lead to occlusion of the vessel a second model was 
explored. 
Perfusion of segments of artery with a 0.257, pronase solution 
had previously been shown to remove the intima and a variable amount of 
49 67 
media from the vessel wall depending on the length of perfusion. * 
These findings were confirmed by Group III of this study. After the 
restoration of normal blood flow, all vessels perfused with pronase 
developed thrombi which completely occluded the lumen within 3 hours. 
In accordance with previously cited observations of thrombosis following 
3 
arterial injury microscopy showed platelets adherent to the damaged 
area of the vessel wall with the formation of fibrin and the trapping of 
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red and white blood cells. The effect of pronase on the vessel wall is 
similar to that resulting from mechanical endarterectomy in that the 
intima and part of the muscularis layers are removed. The 100% 
thrombosis rate after this enzymatic endarterectomy is clearly much 
higher than that resulting from mechanical endarterectomy. However, as 
vessels perfused with saline in Group IV did not show any thrombus 
formation, it was felt that the occlusion rate in Group III did not re¬ 
sult from technical factors. Pronase has been shown in vitro to induce 
21 
platelet aggregation by Davey and Luscher, and it is possible that a 
small amount of pronase remaining on the vessel wall would have a 
direct effect on the blood to enhance thrombus formation. This effect 
was believed to be minimized by flushing the vessel with saline several 
times after the perfusion with pronase and before the restoration of 
blood flow. In addition, it should be noted that the concentration of 
pronase used by Davey to induce platelet aggregation was four times 
that used in the initial perfusate in the present experiments. After 
flushing with saline and restoring blood flow, the pronase would likely 
be diluted even further, so that it seems unlikely that the direct 
action of pronase on platelets was responsible for the 100% thrombosis 
rate. The finding that the Lee White, prothrombin, and partial thrombo¬ 
plastin times were not altered by the addition of small amounts of 
pronase solution to samples of venous blood is some evidence that the 
thrombosis did not result from a direct effect of pronase on the blood. 
It would appear that pronase produces some change in the vessel wall 
which makes it more thrombogenic than a vessel after mechanical endarterec¬ 
tomy although the nature of this change is not clear. 
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Dipyridamole given at a dose of 250 mg per day to the animals 
in Group V appeared to play a role in preventing thrombotic occlusion 
in a significant percentage (70%) of the vessels perfused. This effect 
most likely results from its effects on platelet aggregation. The 
findings in this group correlate well with previous studies demon¬ 
strating the ability of dipyridamole to reduce thrombus formation 
17 18 24 28 
in vivo. 3 3 3 In particular, Danese and Haimov reported that 
100 mg of dipyridamole in 16 kg dogs would decrease the rate of occlu- 
18 
sions 4 hours after endarterectomy. However, Danese, Voleti, and 
Weiss found that 200 mg dipyridamole per day did not decrease the rate 
19 
of occlusion 2 days after endarterectomy or injury with sulphuric acid. 
The reasons for the latter findings are unclear, but in neither of 
these reports was a 1007o rate of occlusive thrombus formation utilized 
as a control. The model using pronase in the present study was employed 
to provide this type of consistently clotting arterial mocel. Signif¬ 
icantly dipyridamole did not inhibit thrombus formation completely as a 
layer of thrombus was demonstrated on the vessel wall 6 hours after 
restoration of blood flow. The effect seemed to be to reduce the growth 
of the thrombus and thus to prevent occlusion of the lumen of the vessel. 
This correlates with the in vitro findings that dipyridamole does not 
affect platelet adhesion to collagen but does decrease the release of 
ADP and serotonin from platelets exposed to collagen as well as decreasing 
the ability of platelets to aggregate in response to ADP.^ 
Aspirin administration to the dogs in Group VI also provided 
significant protection against the development of thrombotic occlusion 
after perfusion with pronase. Both of the series reported by 
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Danese et demonstrated significant protection by aspirin 
against thrombotic occlusion after endarterectomy or chemical injury. 
The dose of aspirin employed in the present study, however, was much 
higher than that used by Danese et ad.., and may be responsible for the 
marked hemorrhagic tendency found. In vitro studies have shown marked 
30 78 8-4 85 
effects of aspirin on platelet aggregation, 5 5 5 and thus it is 
likely that the protection afforded by aspirin in Group VI is also 
mediated by the effects of this drug on platelets. Similar to the ef¬ 
fects of dipyridamole, aspirin did not inhibit thrombus formation but 
did decrease the rate of complete occlusion. 
The ability of dipyridamole and aspirin to reduce the inci¬ 
dence of thrombotic occlusion after enzymatic removal of intima and 
muscularis, as shown in this study, may have clinical application. In 
arterial reconstructive surgery, especially in small vessels, the use 
of either or both of these agents may reduce the early failure rate due 
to thrombosis. As discussed previously, Foster et al. reported that the 
use of low molecular weight dextran immediately postoperatively in¬ 
creased the early patency rate in their series of peripheral vascular 
reconstructions. Similar use of either aspirin or dipyridamole might be 
employed on an experimental basis, ideally in a double blind prospective 
study with patients matched as closely as possible. Such a study seems 
warranted in view of the in vitro findings of the activities of these 
59 
drugs on platelets, the experimental animal work in the present study 
and in those of Danese et 31.,^’^ and the findings of the beneficial 
effects of these agents on platelet turnover and embolic complications 
40 74 
of prosthetic heart valve replacement. ’ The problems with the use 
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of such agents, especially in surgical patients, are obviously those of 
hemostasis. With the systemic administration of a drug with potent 
effects on the primary means of defense against hemorrhage, there is 
certainly risk of significant morbidity and mortality during surgical 
procedures. A more ideal means of preventing thrombosis in a local 
area, such as in reconstruction of a particular arterial system, is to 
apply an agent in that local area which would have effects only in that 
area. Two agents described in the literature would fit these criteria, 
adenosine and Prostaglandin E^. Both agents have very potent effects 
on platelets and both are rapidly degraded in the blood stream. In 
this way, the effects of either agent applied via an intra-arterial 
canula to a particular arterial system might be restricted to that 
arterial system. Unfortunately, dogs will not tolerate an indwelling 
canula over any length of time and it was not possible to test this 
idea against the present model of thrombosis. Ultimately, however, the 
latter approach may be more applicable than the induction of a generalized 








—• Longitudinal section through one side of vessel wall (35X) 
showing thrombus (T) adherent to the media (M) after di¬ 
gestion of the intima and inner layers of media with pro- 
nase. (A) indicates the adventitial surface. 
— Longitudinal section through one side of vessel wall (100X) 
after perfusion with saline. (I) indicates the intact 
intimal layer. (M) represents media. (L) is the lumen of 
the vessel. 
— Longitudinal section through one side of vessel wall (100X) 
from animal treated with dipyridamole 6 hours after perfusion 
with pronase. The amount of thrombus (T) is markedly re¬ 
duced compared to that occurring after perfusion with pro¬ 
nase without prior administration of dipyridamole. (L) and 
(A) represent luminal and adventitial surfaces. There is 
hemorrhage into the medial layer (M) of the vessel wall. 
— Longitudinal section through one side of vessel wall (430X) 
two weeks after perfusion with pronase in animal treated 
with dipyridamole. (F) refers to an area of fibroblastic 
proliferation on the luminal (L) surface of the vessel wall. 
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